Related by context. All words. (Click for frequent words.) 67 Forecast Quick Facts 65 PHARMACEUTICALS 63 Outlook Quick Facts 62 PHARMACEUTICALS INC 62 Coverage Initiated 62 Above Consensus 62 Guidance Quick Facts 62 Update #/#/# #.#a 61 Below Consensus 61 BUSINESS HIGHLIGHTS 61 TriCo Bancshares Announces 60 Osteoporosis Drug 60 Submits NDA 60 Revises FY# EPS 60 Reaffirms FY# EPS 60 Narrows Quick Facts 59 Guides Q4 59 ONCOLOGY 59 Migraine Drug 59 Backs FY# EPS 59 Guides Q2 59 Tops Estimate Update 59 Lifts FY# EPS 59 Backs FY# Revenue 59 View Quick Facts 59 Shows Efficacy 59 Lupus Drug 59 Guides Q1 58 FDA Approvals 58 Lowers FY# EPS 58 Cuts FY# EPS 58 Backs FY# 58 Guides FY# 58 Provides FY# EPS 58 Dividend Declaration 58 CRWESelect.com Stock 58 Crosses Below 58 Stock Gainers 58 Adverse Event 58 NDQ 58 Declares Increase 58 Rheumatoid Arthritis Drug 57 Fourth Quarter Dividend 57 Beats Estimate Update 57 BIOLASE Announces 57 FY# Guidance 57 Wizzard Software Announces 57 Estimates Analyst Blog 57 Investigational Compound 57 Schizophrenia Treatment 57 Generates Record 57 Updates FY# EPS 57 Arthritis Drug 57 Third Quarter Dividend 57 Therapeutic Competitors Companies 57 Orally Active 57 Completes Patient Enrollment 57 Tops Q4 57 Raises FY# EPS 57 Lifts FY# Revenue 57 Presents Preclinical Data 57 Receives Approvable Letter 57 Q4 Adj 57 Carotid Artery Stenting 57 Rises Quick Facts 57 Revenues Decline 57 Jumps Higher 56 Psoriasis Drug 56 Reconfirms 56 1st Quarter Results 56 Weight Loss Drug 56 Therapeutic Competitors Report 56 Shareholder Lawsuit 56 Issues Guidance 56 Misses Q1 56 Revises FY# 56 Guidance Reaffirmed 56 Habersham Bancorp Announces 56 ELLIOTT WAVE 56 Cuts FY# 56 Lifts FY# 56 NASDAQ Listing Requirements 56 Reaffirms FY# Revenue 56 Beats Consensus 56 PharmaVitae Profile 56 PennyOmega.com Stock 56 Reaffirms Outlook 56 Reaffirms Guidance 56 Record Third Quarter 56 Delivers Strong 56 Presents Positive 56 Announce Collaboration Agreement 56 Achieves Positive 56 Drug Fails 55 Approves Quarterly Dividend 55 Provides Updated 55 Maintains FY# 55 Momenta Pharmaceuticals MNTA 55 Guru Bargains 55 See CLINICAL PHARMACOLOGY 55 Boosts Dividend 55 Study Shows Significant 55 Board Authorizes 55 Explore Strategic Alternatives 55 Receives Positive 55 Posts Strong 55 Files IND 55 Summarizes 55 Q2 Adj 55 Q4 Profit Jumps 55 PremierWest Bancorp Announces 55 Margin Expansion 55 www.ONN.tv Reports 55 Provides Guidance 55 Alexza Pharma 55 Affirms FY# 55 Antipsychotic 55 Content Outline 55 Below Estimates 55 Q2 Profit Surges 55 Drops Sharply 55 Initiates Phase III 55 ViroPharma NASDAQ VPHM 55 Q1 Loss Narrows 55 CYTR 55 Virco Announces 55 Atypical Antipsychotics 55 Lifts Dividend 55 FDA Okays 55 Anti Tumor 55 Gets FDA Clearance 55 Integra Lifesciences 54 Surpasses Expectations 54 Trend Toward 54 More Than Doubled 54 Present Preclinical Data 54 Parathyroid Hormone 54 KEY FEATURES 54 Initiates Clinical Trial 54 Q1 Profit Jumps 54 Guides Inline 54 Above Estimates 54 Achieves Primary Endpoint 54 Reaffirms Full 54 Meets Expectations 54 DOSAGE AND ADMINISTRATION 54 Clinical Outcome 54 Misses Q4 54 Boosts FY# 54 Q1 Adj 54 Danazol 54 Clinical Trial Data 54 Quarter Results 54 Kinase Inhibitor 54 SWOT Profile 54 Calcium Acetate 54 Therapeutic Competitors companiesandmarkets.com adEgemonye 54 Q1 Profit Decreases 54 Q1 Profit Surges 54 Lung Cancer Drug 54 Estimate Analyst Blog 54 Fitch Publishes 54 Betaferon R 54 Insulin Glargine 54 Provides Detailed 54 Consolidated Condensed Statement 54 Initiates Clinical 54 Topics Covered 54 External Defibrillators 54 Wider Than Expected 54 TRANSFORMS 54 Roche Boniva 54 Q3 Profit Surges 54 Poniard Pharmaceuticals Announces 54 Announces Definitive Agreements 54 Conjugate 54 #:#-# [006] 54 Transdermal Patch 54 Raises Dividend 54 Announces Effectiveness 54 Profit Leaps 54 Hormonal Contraceptives 54 Regains NASDAQ 54 Glatiramer Acetate 54 Suspends Dividend 54 Vildagliptin 54 Hikes Dividend 54 QLTI 54 Clinical Trial Enrollment 54 Q3 Profit Slips 54 Novel Inhibitor 54 MLNM 54 Reaffirms FY# Earnings 54 Q3 Profit Plunges 54 Quarterly Dividend Payment 54 Backs FY# Earnings 54 Receives NASDAQ 53 Lower Than Expected 53 Pharmacokinetic Study 53 Announces Quarterly 53 Results Exceed Expectations 53 Lowers Guidance 53 iSHARES 53 Q4 Profit Surges 53 2nd Quarter Results 53 Q4 Profit Plunges 53 Net Loss Narrows 53 Raises Quarterly Dividend 53 Exceeds Estimates 53 Record Second Quarter 53 Competitive Position 53 Meets Estimates 53 Revises Q3 53 Fitch Teleconf 53 Consolidation Continues 53 Q3 Profit Jumps 53 Expects Higher 53 Revises Guidance 53 3rd Quarter Results 53 Receives Orphan Drug 53 Analyst initiations 53 Protease Inhibitors 53 Provides Updates 53 Analytical Tool 53 Vertebral Fracture 53 Q3 Loss Narrows 53 Sees Continued Growth 53 Trading Activity 53 Cashflow Report 53 Misses Views 53 Reiterates FY# EPS 53 EXECUTIVE SUMMARY 53 Cilostazol 53 Licenses Novel 53 Demonstrates Potential 53 NOVN 53 Revises Full 53 Annual Meeting Date 53 Narrows Guidance 53 NYSE WYE 53 Presents Preclinical 53 Fourth Consecutive Year 53 Q4 Loss Narrows 53 Q1 Loss Widens 53 Percutaneous Tibial Nerve Stimulation 53 Initiates Phase 2b 53 Momenta Pharma 53 Ticks Higher 53 Share Buyback Program 53 Strongly Supports 53 Provides Update Regarding 53 From Cont 53 Nucleoside 53 JAK Inhibitor 53 Strengthens Balance Sheet 53 Issues Clarification 53 Profit Grows 53 Provides Comprehensive 53 Receives Favorable 53 Analyst Downgrades 52 Dividend Announcement 52 Recombinant Human 52 Neutral Analyst Blog 52 Cautious Outlook 52 J Cardiovasc 52 Q1 Profit Rises 52 Q4 Profit Decreases 52 Anticancer Agent 52 Reaffirms Fiscal 52 Stock Buybacks 52 Q4 Loss Widens 52 Record Fourth Quarter 52 Cubist Pharma 52 Lowers Q4 52 Cites Positive 52 Pro Forma EPS 52 Q2 Profit Drops 52 Alkeran 52 Rises Sharply 52 Febuxostat 52 Ups Dividend 52 Regains Compliance 52 Results Reflect 52 Q2 Profit Climbs 52 Significant Increase 52 MARKET INSIGHT 52 Tops Views 52 Earnings Announcements 52 Q1 Profit Soars 52 Sees Wider 52 3Q Profit Drops 52 Fiscal Second Quarter 52 Posts Solid 52 Host Teleconference 52 Increases Cash Dividend 52 Stock Plunges 52 Hypercholesterolemia 52 Filing Status 52 Anticancer Drug 52 Sanofi NYSE SNY 52 Cramer Likes 52 Reaffirms FY# 52 Volume Detected 52 Q1 Profit Declines 52 Subsidiaries Consolidated Statement 52 FRESENIUS 52 Announces Share Buyback 52 Package Insert 52 Confirms Receipt 52 Revises Q4 52 Issues Shareholder 52 SWOT Analysis Aarkstore Enterprise 52 Posts Wider Loss 52 Therapeutic Competitors 52 Efficacy Study 52 Misses Q3 52 FFO Per Share 52 Q3 Profit Rises 52 Ondansetron Orally Disintegrating Tablets 52 Preliminary Third Quarter 52 F#Q# Earnings 52 Increases Quarterly Dividend 52 Anticipates Strong 52 Companies Mentioned 52 Posts 4Q 52 Tops Expectations 52 Q2 Profit Plunges 52 Diagnostic Criteria 52 4Q Profit Slides 52 4Q Profit Surges 52 Tightens FY# 52 Drug Eluting Stents 52 Q1 Profit Drops 52 Q2 Loss Narrows 52 Boosts Quarterly Dividend 52 Prospective Randomized 52 Announces Dividend 52 Benign Prostatic Hyperplasia 52 Announces Organizational Changes 52 Pending Acquisition 52 Report Indicates 52 Receptor Agonist 52 Rising Sharply 52 Anounces 52 Nasdaq ACHN 52 Preclinical Study 52 Q4 Profit Climbs 52 Cuts Dividend 52 Sono Tek Announces 52 Randomized Study 52 Subsidiaries CONSOLIDATED 52 Preliminary Fourth Quarter 52 Regulatory Submissions 52 Delivers Solid 51 Raises PT 51 Bodes Well 51 Updates Guidance 51 Salix Pharma 51 Biggest Gainers 51 #Q# Earnings Release 51 Q2 Loss Widens 51 Aarkstore 51 Declares Regular Cash Dividend 51 widens Quick Facts 51 Quarter Earnings Release 51 Completes Integration 51 Upward Revision 51 Achieves Record Sales 51 3Q Profit Rises 51 SEACOR Holdings Announces 51 1Q Profit Dips 51 Announces Stockholder Approval 51 Atelvia 51 Finacea 51 OW Rating 51 Q1 Profit Plunges 51 Reports Significantly Improved 51 epoetin zeta 51 Recommends Changes 51 OSI Pharma 51 Gains Traction 51 CHANGES IN ACCOUNTING POLICIES 51 Upcoming Presentation 51 Mitigates 51 Zoloft sertraline 51 Teva Pharm 51 Posts Smaller 51 Given Underperform Rating 51 Prognostic Value 51 Posts 2Q 51 Boosts Outlook 51 Q3 Loss Widens 51 Misses Expectations 51 Q3 Profit Plummets 51 Shares Plummet 51 Dividend Payment 51 Exceeds Expectations 51 Novel Therapeutic 51 Oligonucleotides 51 Ltd Therapeutic Competitors 51 Narrows Loss 51 Decline Quick Facts 51 Announces Effective Date 51 Increases Guidance 51 Posts Third Quarter 51 Earnings Surge 51 Receives Milestone Payment 51 Profit Sinks 51 Q4 Profit Rises 51 Announces Restatement 51 Undiscovered Gem 51 NASDAQ ONXX 51 Ups Guidance 51 FDX UPS 51 Q4 Profit Declines 51 Earnings Soar 51 Misses Estimate 51 Boosts Estimates 51 Genes Involved 51 Boniva ibandronate 51 Earnings Decline 51 Remains Neutral 51 Growth Exceeds Expectations 51 Successfully Completes Phase 51 Small Molecule Drug 51 Upcoming Webinar 51 Outperformed 51 Angiotensin Converting Enzyme 51 Profit Dips 51 Q1 Profit Climbs 51 StockPreacher.com Issues Trading 51 Sees Positive 51 Multicenter Phase 51 lovastatin Mevacor 50 Daptomycin 50 Inc Therapeutic Competitors 50 Favorable Ruling 50 Exceed Guidance 50 Suicidality 50 Earnings Guidance 50 Re Affirms 50 Recommends Rejection 50 Q2 Profit Rises 50 Receives Commitment 50 Announces Favorable 50 Isis Pharma 50 Fluconazole 50 Beats Expectations 50 Revised Guidance 50 Cardiotoxicity 50 Q4 Profit Soars 50 TKPHF 50 Maintains Strong 50 Temporarily Suspends 50 Observational Study 50 Hold Fourth Quarter 50 Q4 Profit Slips 50 Profits Jump 50 Synaptics Incorporated SYNA 50 Preliminary Second Quarter 50 Drug Shows Promise 50 Lowers Price 50 Delays Filing 50 Announces Revised 50 Q3 Adj 50 Organizational Changes 50 Drug Interactions 50 Epoetin 50 Cuts Costs 50 Increases Quarterly Cash Dividend 50 HDAC Inhibitor 50 Beats Estimate 50 Reiterates Guidance 50 Maxalt 50 Files Amended 50 GlaxoSmithKline Requip 50 Penwest Pharma 50 Surpasses Estimates 50 Margin Improvement 50 Boosts Profit 50 Bellwether Interviews 50 Sets Second Quarter 50 Selects Trintech 50 Increases Dividend 50 RGEN 50 Revises Third Quarter 50 Reduces Debt 50 Completes Transition 50 Planned Acquisition 50 Tyrosine Kinase Inhibitor 50 INFI 50 Pro Forma Results 50 Analyst Expectations 50 Gives Cautious 50 Host Webcast 50 Achieves Profitability 50 Antibacterials 50 Sets Record Date 50 NSABP B 50 Receives Requisite Consents 50 Prospective Multicenter 50 ROCA Reports 50 CFO Resigns 50 Releases Audited 50 Boosts Buyback 50 Ziprasidone 50 Bearish MACD 50 Impax Laboratories Inc 50 Reschedules Second Quarter 50 Declares Regular Quarterly Dividend 50 Expands Capabilities 50 Directors Authorizes Additional 50 Sustained Release 50 Lowers 4Q 50 Retinal Vein Occlusion 50 Posts Narrower Loss 50 Announces Presentation 50 2Q Loss Narrows 50 Adventrx Pharmaceuticals 50 Posts 3Q Profit 50 Identifies Key 50 Expects Significant 50 Presents Positive Preclinical 50 Stock Buyback Program 50 Revises Fourth Quarter 50 Interferon Alpha 50 Key Takeaways 50 Boosts Share Buyback 50 Fulvestrant 50 Successfully Concludes 50 Ratings Unaffected 50 Sharpen Focus 50 Issues Surrounding 50 Reiterates Buy 50 Provides Preliminary 50 Celexa citalopram 50 Stock Buyback 50 Gastrointestinal Stromal Tumors 50 NASDAQ UTIW 50 Narrower Loss 50 Q2 Profit Declines 50 Files Shelf Registration Statement 50 - Three MZigWheels 50 Q3 Profit Soars 50 Analogs 50 Atopic Dermatitis 50 Extended Release tablets 50 Present Webinar 50 Biomarker Study 50 Releases Second Quarter 50 Differences Between 50 Guidance Disappoints 50 Expands Coverage 50 Preclinical Models 50 1Q Earnings 50 Options Expensing 50 Webcast Presentations 50 Narrows 4Q Loss 50 Achieves Significant 50 Misses Estimates 50 Ambrisentan 49 Raises Estimates 49 Transdermal Delivery 49 Enhance Shareholder Value 49 Antiepileptic Drug 49 4Q Loss 49 Proposed Changes 49 Revises Fiscal 49 Revises Earnings 49 Releases Latest 49 Product Offerings 49 Chemotherapeutic Agents 49 -Bascetta 49 Earnings Climb 49 Raises Outlook 49 Completes Divestiture 49 Protelos R 49 Outlines Strategy 49 Publicizes 49 Sirolimus eluting 49 Quantifies 49 ANADIGICS Announces 49 Regains Compliance With 49 Hits Lowest Level 49 Provide Comprehensive 49 Reschedules Fourth Quarter 49 Fitch Teleconference 49 Stays Neutral 49 Maven Semantic http:/www.mavensemantic.com announBruising Brandon 49 Tenormin 49 Nasdaq SHPGY 49 Q3 Profit Declines 49 Alexion Soliris 49 Share Repurchases 49 Q1 Profit Dips 49 Hold Third Quarter 49 Anti CD# Antibody 49 Pharmaceuticals Initiates 49 Cancer Res 49 Reporting Requirements 49 Mean Reversion 49 Profit Edges Up 49 Resumes Coverage 49 4Q Loss Narrows 49 Raises Guidance 49 Rated Speculative Buy 49 Maintains Hold 49 Small Molecule 49 Oxcarbazepine 49 Topiramate Tablets 49 Slide Presentation 49 Schedules Earnings 49 Hepatocellular Carcinoma 49 Initiates Quarterly 49 Aurora Kinase 49 Lowers Outlook 49 Analyst Downgrade 49 Funds Announce 49 Performance Benchmarks 49 Q2 Profit Soars 49 Multiple Ascending Dose 49 Protein Expression 49 Trandolapril 49 Scaling Back 49 Neuroprotective Effects 49 Pazopanib 49 #M Stock Buyback 49 Better Than Expected 49 Sees Upside 49 Reiterates Buy Rating 49 Inc. OTC MGRN 49 Announces Share Repurchase 49 Extends Collaboration 49 Cytokinetics CYTK 49 Begins Clinical Trial 49 Oxybutynin 49 Fiscal Third Quarter 49 Schedules Earnings Release 49 Biopharmaceutical Industry 49 Shareholders Approve Name 49 Begin Coverage 49 Authorizes Additional 49 Cost Structure 49 Antifungals 49 Systemic Delivery 49 Oral Insulin 49 Beats Zacks 49 SPIRIVA ® 49 Reaffirms Earnings 49 1Q Loss Narrows 49 Qiagen NASDAQ QGEN 49 efavirenz EFV 49 Q4 Profit Drops 49 Files Annual Report 49 Kevin Matras Highlights 49 Declares Dividend 49 Lowers FY# 49 Completes Restatement 49 Expects Fourth Quarter 49 Sixth Consecutive Year 49 2Q Profit Surges 49 Maintains Buy 49 2Q Profit Up 49 Fell Sharply 49 Successfully Deploys 49 Phase III Clinical Trials 49 Profits Tumble 49 Seroquel quetiapine 49 Fosamax alendronate 49 Jumpstarts 49 Subsidiaries Selected Financial 49 Discuss Fourth Quarter 49 Zacks Analyst Interview 49 Glaxo GSK 49 Schedules Fiscal 49 Sees Profits 49 Second Quarter Earnings Announcement 49 Significantly Expands 49 Announces Profitable 49 Fourth Quarter Results 49 Debt Issuance 49 Momentum Continues 49 Buy Rating Maintained 49 Oxymorphone ER 49 Publishes Updated 49 Conference Call TRANSCRIPT 49 Myriad Genetics Inc 49 Cannabinoid 49 Oxytrol R 49 Zix Corporation Announces 49 serotonin norepinephrine reuptake inhibitor 49 Webcast Second Quarter 49 Issues Statement Regarding 49 Cost Reductions 49 Epirubicin 49 Profit Exceeds Estimates 49 Sees Weak 49 Sharpens Focus 49 Receives Early Termination 49 2Q Profit Down 49 4Q Profit Jumps 49 Updates Fourth Quarter 49 Enters Definitive Agreement 48 Targeted Therapies 48 Reschedules Third Quarter 48 Tumor Targeting 48 Analyst Upgrade 48 Easily Beats 48 Protein Biomarker 48 Report Identifies 48 Report Examines 48 Greatly Improves 48 Posts 1Q 48 Approves Share Repurchase 48 Commences Phase III 48 Sets Fourth Quarter 48 Increases Share Repurchase 48 Lags Estimates 48 4Q Loss Widens 48 L.P. Announces 48 BioSyent TSX VENTURE 48 Schedules 3Q 48 Fiscal Fourth Quarter 48 Completes Transaction 48 4Q Profit Slips 48 RedChip Visibility Issues 48 Receives Notification 48 4Q Earnings 48 Stakeholder Opinions 48 Oncology Compounds 48 Lowers Estimates 48 Metabolic Endocrinology 48 Antigen CEA 48 NASDAQ Delisting 48 1Q Profit Slides 48 Sees 3Q 48 Elagolix 48 Actonel risedronate 48 Ticagrelor 48 Insider Trades 48 receptor modulators 48 Restate Results 48 Substantially Increases 48 Recommends Dividend 48 Positions Itself 48 Nasdaq IPXL 48 Consulting Fees Honoraria 48 Sees 1Q 48 Files Shelf Registration 48 Schedules 2Q 48 Announces Divestiture 48 Webcast Fourth Quarter 48 Streamlines Operations 48 Hepatic Encephalopathy 48 1st Quarter Earnings 48 Profits Decline 48 Reaches Definitive Agreement 48 Double Digit Revenue 48 Report Analyzes 48 4Q Profit Falls 48 Restates Earnings 48 Posts 3Q 48 Vascular Targeting Agents 48 Releases Third Quarter 48 Enters Oversold Territory 48 1Q Loss Widens 48 Rapidly Evolving 48 MEMY 48 Posts 4Q Loss 48 1Q Profit Drops 48 CORPORATE DEVELOPMENTS 48 2Q Profit 48 Subsidiary Files 48 Hold Teleconference 48 Commences Consent Solicitation 48 Become Fully 48 Zenvia Phase III 48 Earnings Postmortem 48 Q3 Profit Drops 48 Declares Quarterly Cash Dividend 48 EYET 48 Announces Webcast 48 Posts Lower 48 Files Restated 48 Positive Cash Flow 48 Announces Job Cuts 48 Announces Expanded 48 Reports Wider Loss 48 Host Fourth Quarter 48 Reclassifies 48 Ortho Cept 48 Sees Continued 48 4Q Profit Drops 48 Finalizes Plans 48 Announces Rescheduling 48 Introduces Enhanced 48 AM Vitals 48 Reaches Profitability 48 Teva Pharma 48 Risk Stratification 48 Temsirolimus 48 Finalizes Sale 48 Reiterates Fiscal 48 DAYTRANA TM 48 Fourth Quarter Fiscal 48 Disease Modification 48 Guides Above 48 Segment Highlights 48 NASDAQGS 48 Product Monograph 48 Directors Declares Quarterly 47 UCB Keppra 47 Profitable Quarter 47 Cancer Biomarkers 47 Stock Repurchases 47 Sees 3Q Profit 47 GW# [003] 47 Seventh Consecutive Year 47 4Q Profit Soars 47 Improves Customer Experience 47 Critical Component 47 Competitor Report 47 Workforce Reduction 47 Safinamide 47 Regains Full 47 ZETIA ezetimibe 47 Orally Disintegrating 47 Therapeutic Monoclonal Antibodies 47 Detailed Product 47 Bazedoxifene 47 Delivers Unprecedented 47 Q1 Profit Slips 47 Refines 47 1Q Profit Slips 47 4Q Profit Down 47 Revises Upward 47 Guides Below 47 Cancer Vaccines 47 Profit Misses 47 Maintains Neutral 47 Revises Second Quarter 47 3Q Earnings 47 Has Spiked 47 Webcast Third Quarter 47 Adverse Reactions 47 Initiated Phase 47 Host Third Quarter 47 Consumer Conf 47 Gene Silencing 47 2Q EPS 47 Minimal Impact 47 Inflammatory Disease 47 Expands Share Repurchase 47 Introduces Expanded 47 Profit Beats Expectations 47 Outlines Strategies 47 Schedules Third Quarter Fiscal 47 3Q 4Q 47 Lowers Forecast 47 Avanafil 47 Sertraline 47 Reinforces Commitment 47 Updates Shareholders 47 Achieves Record Growth 47 Continues Steady 47 Erlotinib 47 pregabalin Lyrica 47 1Q Profit Up 47 Nasdaq Delisting 47 2Q Profit Drops 47 Launches Redesigned Website 47 Alnylam ALNY 47 Restates 47 Realigns 47 Sets Third Quarter 47 Gene Expression Analysis 47 Nitrolingual 47 Sporanox 47 Unveils Expanded 47 1Q Profit Falls 47 Rebif ® 47 Glaxosmithkline Plc 47 ILLUSTRATE 47 Announces Stock Buyback 47 3Q Profit Down 47 Investor Conf 47 Mutational 47 Lowered Guidance 47 Approves Stock Buyback 47 prasugrel Effient 47 Zacks Investment Ideas 47 Enters Into Agreements 47 Ownership Structure 47 Sees Opportunity 47 humanized monoclonal 47 Sees 4Q 47 Profit Slides 47 ZOCOR 47 Underwrites 47 Estrogen Receptor 47 phase IIIb 47 #:#-# [001] 47 Sees Modest 47 Bioavailability 47 Schedules Second Quarter 47 Compelling Case 47 Expects 1Q 47 Consolidates Operations 47 Pharmacodynamic 47 Forest Labs FRX 47 Demonstrates Commitment 47 Reports Narrower Loss 47 Schaeffer Option Activity 47 Organizational Structure 47 3Q Loss Narrows 47 Stockholders Approve 47 PharmaVitae 47 Retools 47 Interferon Alfa 47 CAS #-#-# Market [001] 47 Tops Estimates 47 SurModics SRDX 47 Vascular Targeting 47 PROTONIX 47 Pharmacokinetic PK 47 Extends Maturity 47 Particle Size Analyzer 47 Achieves Record Revenue 47 Restate Earnings 46 3Q Loss Widens 46 Schedules Fourth Quarter 46 Xenoport Inc 46 Adopts Stockholder Rights 46 Pending Merger 46 Depomed DEPO 46 Venlafaxine 46 Second Quarter Results 46 Profit Quadruples 46 Drilling Activity 46 Protein Kinase 46 Expresses Disappointment 46 Auxilium Pharma 46 Olmesartan 46 2Q Loss Widens 46 Schaeffer Option 46 Intravenous Equipment 46 Gene Expression Profiling 46 Compiles 46 Mylan Nasdaq MYL 46 Pharmacueticals 46 RADIANCE 46 Q3 Earnings Announcement 46 Vimpat lacosamide 46 2Q Loss 46 Affymax AFFY 46 Exploring Strategic Alternatives 46 Beats Analyst 46 Announces Accelerated Vesting 46 Increases Buyback 46 Sees Significant 46 sitagliptin Januvia 46 Economist Predicts 46 Ups Quarterly Dividend 46 TERANODE 46 Challenges Loom 46 Schedules Webcast 46 Delivers Comprehensive 46 1Q Profit Down 46 3Q Profit Falls 46 Q2 Profit Plummets 46 Fitch Assigns BBB 46 3Q Profit Climbs 46 Unveils Next Generation 46 SmPC 46 PROMETHEUS 46 Valsartan 46 4Q Profit Dips 46 Aruvian R'search presents 46 Restate Financial 46 Posts 2Q Profit 46 Effexor venlafaxine 46 multicenter multinational 46 Lowers 1Q 46 2Q Profit Soars 46 Anticancer Agents 46 Posts 2Q Loss 46 3Q Profit Surges 46 Medicis Pharmaceutical Corp 46 Reports Sharply Higher 46 Expandable Polystyrene 46 Provides Operational 46 Escitalopram 46 Earnings Scorecard 46 Fundamental Strength 46 Reaffirms Fourth Quarter 46 Increases Stock Buyback 46 Hold Second Quarter 46 Idenix Pharmaceuticals 46 Novel Therapies